Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project

1] INSERM U830, Laboratoire de Génétique et Biologie des Cancers, Institut Curie, Paris, France [2] Département d'Oncologie Pédiatrique, Institut Curie, 26 rue d'Ulm, Cedex 05, Paris 75248, France.
British Journal of Cancer (Impact Factor: 4.82). 09/2012; 107(8):1418-22. DOI: 10.1038/bjc.2012.375
Source: PubMed

ABSTRACT Background:In the INRG dataset, the hypothesis that any segmental chromosomal alteration might be of prognostic impact in neuroblastoma without MYCN amplification (MNA) was tested.Methods:The presence of any segmental chromosomal alteration (chromosome 1p deletion, 11q deletion and/or chromosome 17q gain) defined a segmental genomic profile. Only tumours with a confirmed unaltered status for all three chromosome arms were considered as having no segmental chromosomal alterations.Results:Among the 8800 patients in the INRG database, a genomic type could be attributed for 505 patients without MNA: 397 cases had a segmental genomic type, whereas 108 cases had an absence of any segmental alteration. A segmental genomic type was more frequent in patients >18 months and in stage 4 disease (P<0.0001). In univariate analysis, 11q deletion, 17q gain and a segmental genomic type were associated with a poorer event-free survival (EFS) (P<0.0001, P=0.0002 and P<0.0001, respectively). In multivariate analysis modelling EFS, the parameters age, stage and a segmental genomic type were retained in the model, whereas the individual genetic markers were not (P<0.0001 and RR=2.56; P=0.0002 and RR=1.8; P=0.01 and RR=1.7, respectively).Conclusion:A segmental genomic profile, rather than the single genetic markers, adds prognostic information to the clinical markers age and stage in neuroblastoma patients without MNA, underlining the importance of pangenomic studies.


Available from: Susan L Cohn, Feb 19, 2014
  • [Show abstract] [Hide abstract]
    ABSTRACT: Neuroblastoma is a developmental tumor of young children arising from the embryonic sympathoadrenal lineage of the neural crest. Neuroblastoma is the primary cause of death from pediatric cancer for children between the ages of one and five years and accounts for ∼13% of all pediatric cancer mortality. Its clinical impact and unique biology have made this aggressive malignancy the focus of a large concerted translational research effort. New insights into tumor biology are driving the development of new classification schemas. Novel targeted therapeutic approaches include small-molecule inhibitors as well as epigenetic, noncoding-RNA, and cell-based immunologic therapies. In this review, recent insights regarding the pathogenesis and biology of neuroblastoma are placed in context with the current understanding of tumor biology and tumor/host interactions. Systematic classification of patients coupled with therapeutic advances point to a future of improved clinical outcomes for this biologically distinct and highly aggressive pediatric malignancy. Expected final online publication date for the Annual Review of Medicine Volume 66 is January 14, 2015. Please see for revised estimates.
    Annual Review of Medicine 10/2014; 66(1). DOI:10.1146/annurev-med-011514-023121 · 15.48 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: In neuroblastoma (NB), MYCN genomic amplification and segmental chromosomal alterations including 1p or 11q loss of heterozygocity and/or 17q gain are associated with progression and poor clinical outcome. Segmental alterations are the strongest predictor of relapse and result from unbalanced translocations attributable to erroneous repair of chromosomal breaks. Although sequence analysis of affected genomic regions suggests these errors arise by non-homologous end-joining (NHEJ) of DNA double-strand breaks (DSB), abnormalities in NHEJ have not been implicated in NB pathogenesis. On this basis, the hypothesis that an error-prone mechanism of NHEJ is critical for NB cell survival was tested. Plasmid-based DSB repair assays demonstrated efficient NHEJ activity in human NB cells with repair products that were error-prone relative to non-transformed cells. NB cells derived from tumorigenic neuroblastic phenotypes had differential DNA repair protein expression patterns compared to non-tumorigenic cells. Tumorigenic NB cells were deficient in DNA ligase IV (Lig4) and Artemis (DCLRE1C), mediators of canonical NHEJ. Conversely, enzymes required for an error-prone alternative NHEJ pathway (alt-NHEJ), DNA Ligase IIIα (Lig3), DNA Ligase I (Lig1), and poly (ADP-ribose) polymerase-1 protein (PARP1) were upregulated. Inhibition of Lig3 and Lig1 led to DSB accumulation and cell death, linking alt-NHEJ to cell survival in NB. NB cells demonstrated sensitivity to PARP1 inhibition (PARPi) that paralleled PARP1 expression. In a dataset of human NB patient tumors, overexpression of genes encoding alt-NHEJ proteins associated with poor survival. Implications: These findings provide insight into DNA repair fidelity in NB and identify components of the alt-NHEJ pathway as promising therapeutic targets. Copyright © 2014, American Association for Cancer Research.
    Molecular Cancer Research 01/2015; 13(3). DOI:10.1158/1541-7786.MCR-14-0337 · 4.50 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Neuroblastoma is the most common extracranial solid tumor in childhood in high-income countries (HIC), where consistent treatment approaches based on clinical and tumor biological risk stratification have steadily improved outcomes. However, in low- and middle- income countries (LMIC), suboptimal diagnosis, risk stratification, and treatment may occur due to limited resources and unavailable infrastructure. The clinical practice guidelines outlined in this manuscript are based on current published evidence and expert opinions. Standard risk stratification and treatment explicitly adapted to graduated resource settings can improve outcomes for children with neuroblastoma by reducing preventable toxic death and relapse. Pediatr Blood Cancer © 2015 The Authors. Pediatric Blood & Cancer, published by Wiley Periodicals, Inc. © 2015 The Authors. Pediatric Blood & Cancer, published by Wiley Periodicals, Inc.
    Pediatric Blood & Cancer 03/2015; DOI:10.1002/pbc.25501 · 2.56 Impact Factor